In Mice, The Fountain Of Youth May Lie in Blocking a Single Immune Receptor

A neutrophil’s life is short. Born in the bone marrow, it spills into the blood as the body’s first responder and within eight to twelve hours it is already turning. It goes rogue, in a sense, curdling into a bloated, toxic version of itself that leaks proteins and flings out sticky webs meant for pathogens but landing, instead, on the living tissue next door. More than 100 billion of these cells roll off the line every day in a human body. Something has to haul the spent ones away before they do damage.

This is the task of the macrophage. A new study in mice by Stanford University suggests the slow failure of that garbage cleanup is one of the reasons we grow old. Not a metaphor for aging, the researchers argue, but a mechanical cause of it.

The clean-up crew in question is a particular kind called a tissue-resident macrophage, or TRM, one of the long-lived cells that reside inside an organ before birth and stay put for life. TRMs make up 60 to 90 per cent of all macrophages in the brain, liver, heart, lungs and kidneys and one of their standing duties is efferocytosis: swallowing up the dead, dying, senescent material before any of it turns septic. “They’re the body’s garbage collection crew,” says Katrin Andreasson, a neurologist at Stanford Medicine, who led the work. “A lot of that garbage is defunct cells.” More specifically, a significant amount of the trash is made up of worn-out neutrophils.

The trouble is, as a mouse ages, its resident macrophages get sluggish and the spent neutrophils they are meant to eat begin to pile up in the tissues instead.

Andreasson’s team traced that sluggishness to a single receptor. Sitting on the surface of these macrophages is a docking point called EP2, which responds to prostaglandin E2 (PGE2), a lipid messenger the body pumps out during inflammation. With age, both the messenger and the receptor become more abundant and the constant EP2 signalling throttles the macrophage’s ability to wolf down neutrophils. The cells that should be doing the clearing simply can’t keep up.

So the group built a mouse in which the EP2 gene could be switched off on command only in the tissue-resident macrophages. “We’ve shown that when tissue-resident macrophages don’t have EP2 on their surfaces anymore or when that receptor is plugged up by a drug, this decline doesn’t happen,” says Andreasson.

Switching Off EP2 Kept Multiple Organs Significantly Younger

The effect in the animals was not subtle. Old mice engineered to lose EP2 kept the mitochondrial fitness of much younger animals and they held off the familiar wreckage of age across organ after organ: less frailty, less visceral fat, more muscle, steadier hearts, sharper memory in a maze. To find out what was travelling between the organs, the team ran the plasma proteome across cohorts of 4 to 13 mice per group, cataloguing the proteins circulating in the blood. Of 138 proteins they could pin down, 71 shifted substantially with age. In the mice missing TRM EP2, 59 of those stayed at youthful levels. Many traced back to one place: “The liver is one of the body’s most tissue-resident-macrophage-enriched organs and a major contributor to aging-related changes in blood chemistry,” Andreasson says. Peer into the liver, spleen and bone marrow of a normal old mouse and you find the senescent neutrophils heaped up; peer into the EP2-less ones and the heaps are largely gone.

Why neutrophils and not just any dead cell? Because clearing them turns out to be a two-step problem and aging breaks the harder step. A macrophage first has to recognise its target, then physically grip it, using clutches of surface proteins called integrins, before it can engulf it. The recognition machinery falters a bit with age across all sorts of debris. But the gripping machinery, the study found, falls apart specifically for senescent neutrophils: the coactivators that snap an integrin into its high-grip shape (Rac1, RhoA and three others) drop away in old macrophages, and switching off EP2 brings them back. In a dish, old macrophages cleared senescent neutrophils roughly tenfold worse than young ones and around sixfold worse than the EP2-deleted cells. For ordinary apoptotic cells the gap was only about 2.5 times. Senescent neutrophils, in other words, are the substrate that suffers most when the crew slows down.

What the Mouse Result Does Not Prove About People

All of this is a mouse story and it’s important to remember that. It is also, so far, a story about male mice: the published experiments used males throughout, which leaves the question of whether the same holds in females open.

The human evidence is thinner and softer. Digging into published single-cell atlases of human liver and heart, the team saw the same fingerprint, TRMs thinning out, EP2 climbing, neutrophils drifting toward a senescent state and more so in diseased tissue than merely old tissue. But this is pattern-matching, by the authors’ own admission, not proof that blocking EP2 would rejuvenate a person. The Stanford release leans harder on human health-spans than the paper does; the paper keeps that line bright.

That said, the drug arm is where things get interesting. The team treated ordinary old mice, no genetic tinkering, with an experimental EP2 blocker called PF-04418948 for two months and it pushed senescent neutrophil counts back toward youthful levels and restored the macrophages’ appetite, most completely in the liver. There is no approved drug that shuts down EP2 alone: the everyday painkillers that touch this pathway (aspirin and its kin) throttle PGE2 production wholesale and hit other useful prostaglandins in the bargain. Andreasson’s ask is narrower. “We need to develop a safe drug,” she says, one that plugs EP2 without meddling upstream.

What lingers is the reframing. If this holds, aging is less a passive wearing-out than an active failure to take out the trash, and taking-out-the-trash is a thing a molecule might be persuaded to resume. “We’ve been trying to figure out why we age,” says Andreasson. “Now we know at least one big reason for it.” A big reason, she is careful to say. Not the only one.

Frequently Asked Questions

How does failing to clear old immune cells actually make a body age?

Failing to clear old immune cells appears to age a body because worn-out neutrophils, if left in the tissues, leak toxic proteins and inflammatory webs that injure and inflame their neighbours. In aged mice, the resident macrophages meant to eat those spent neutrophils slow down, the debris accumulates, and organs from the heart to the brain show the wear that follows. Restoring the clean-up in these animals held that damage off.

Could blocking the EP2 receptor become an anti-aging drug for people?

Blocking EP2 is a promising lead rather than a ready anti-aging drug for people. An experimental blocker restored neutrophil clearance in old mice, and aged human tissues show the same molecular pattern, but the human data are correlative and no drug yet shuts down EP2 on its own without disturbing other useful signalling. Everyday anti-inflammatories act higher up the same pathway and are not a substitute.

Is it true that this reverses aging?

It is not quite true that this reverses aging and the distinction matters. In mice, switching off the EP2 receptor mostly prevented age-related decline from setting in, while a two-month course of an EP2-blocking drug in already-old animals pushed some markers back toward youthful levels. The work was done in male mice and reanalysed human tissue, so it is a mechanism and a candidate target, not a demonstrated treatment.

Why do neutrophils in particular cause so much trouble as we age?

Neutrophils cause outsized trouble with age because there are so many of them – more than 100 billion made daily in a human body – and they turn toxic within hours if not cleared. The study found that aged macrophages lose the specific gripping step needed to engulf senescent neutrophils, so these cells pile up faster than other debris and drive local inflammation in the tissues where they land.